1. Preliminary Estimates from the 1995 National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administration, U.S. Department of Health and Human Services, Rockville, 1996.

2. Abadji V, Lin S, Taha G, et al. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 1994;37:1889-1893.

3. Abel EL. Effects of prenatal exposure to cannabinoids. In: Pinkert TM, ed. Current research on the consequences of maternal drug abuse. Washington, D.C.: U.S. Govt. Printing Office, 1985;20-35.

4. Aceto M, Scates S, Lowe J, Martin B. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 1995;282:R1-R2.

5. Aceto M, Scates S, Lowe J, Martin B. Dependence on D9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996;278:1290-1295.

6. Adams IB, Ryan W, Singer M, et al. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J Pharmacol Exp Ther 1995;273:1172-1181.

7. Allebeck P. Schizophrenia and cannabis: Cause-effect relationship? In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, epidemiology, detection. Boca Raton, FL: CRC Press, 1993;113-117.

8. Aussedat M, Niziolek-Reinhardt S. Detection of cannabis and other drugs in 120 victims of road accidents. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, epidemiology, detection. Boca Raton, FL: CRC Press, 1993;73-77.

9. Beardsley PM, Balster RL, Harris LS. Dependence on tetrahydrocannabinol in rhesus monkeys. J Pharmacol Exp Ther 1986;239:311-319.

10. Bhattacharya SK. D9-Tetrahydrocannabinol increases brain prostaglandins in the rat. Psychopharmacology 1986;90:499.

11. Budney AJ, Knadel DB, Cherek DR, Martin BR, Stephens RS, Roffman R. College on Problems of Drug Dependence Meeting, Puerto Rico (June, 1996): Marijuana use and dependence. Drug Alcohol Depend 45;1-11, 1997

12. Burstein S. Eicosanoids as mediators of cannabinoid action. In: Murphy L, Bartke A, eds. Marijuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press, 1992;73-91.

13. Cadas H, Gaillet S, Beltramo M, Venance L, Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci 1996;16:3934-3942.

14. Chait LD, Pierri J. Effects of smoked marijuana on human performance: A critical review. In: Murphy L, Bartke A, eds. Marijuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press, 1992;387-423.

15. Childers SR, Sexton T, Roy MB. Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 1994;47:711-715.

16. Clapp JFI, Wesley M, Cooke R, Pekala R, Holstein C. The effects of marijuana smoke on gas exchange in ovine pregnancy. Alcohol Drug Res 1987;7:85-92.

17. Collins DR, Pertwee RG, Davies SN. Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br J Pharmacol 1995;115:869-870.

18. Compton D, Aceto M, Lowe J, Martin B. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): Inhibition of D9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 1996;277:586-594.

19. Compton DR, Dewey WL, Martin BR. Cannabis dependence and tolerance production. In: Erickson CK, Javors MA, Morgan WW, eds. Addiction potential of abused drugs and drug classes. Binghampton, N.Y.: The Hayworth Press, Inc., 1990;129-147.

20. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: Classification as cannabimimetic agents. J Pharmacol Exp Ther 1992;260:201-209.

21. Compton DR, Rice KC, De Costa BR, et al. Cannabinoid structure-activity relationships: Correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 1993;265:218-226.

22. Deutsch DG, Chin SA. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 1993;46:791-796.

23. Devane W, Axelrod J. Characterization of the enzymatic synthesis of anandamide: Properties and distribution in the brain. Neuropsychopharmacology 1994;10:146S-146S.

24. Devane W, Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor by brain membranes. Proc Natl Acad Sci USA 1994;91:6698-6701.

25. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988;34:605-613.

26. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-1949.

27. Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;38:151-178.

28. Dewey WL, Harris LS, Howes JF, et al. Pharmacology of some marijuana constituents and 2 heterocyclic analogues. Nature 1970;226:1265-1267.

29. Dewey WL, Martin BR, Beckner JS, Harris LS. A comparison of the subcellular distribution of cannabinoids in the brains of tolerant and nontolerant dogs, rats, and mice after injecting radiolabeled D9-tetrahydrocannabinol. In: Nahas GG, eds. Marihuana: Chemistry, biochemistry, and cellular effects. New York: Springer-Verlag, 1976;349-365.

30. Di Marzo V, Fontana A, Cadas H, et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994;372:686-691.

31. Eldridge JC, Landfield PW. Cannabinoid-glucocorticoid interactions in the hippocampal region of the brain. In: Murphy L, Bartke A, eds. Marijuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press, 1992;93-117.

32. Engstrom A, Allebeck P, Rodwall Y, Rydberg U. Adverse psychic effects of cannabis—with special focus on Sweden. In: Harvey DJ, Paton W, Nahas G, eds. Marijuana '84: Proceedings of the oxford symposium on cannabis. Oxford: IRL Press, 1985;593-604.

33. Fan F, Tao Q, Abood M, Martin BR. Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. Brain Res 1996;706:13-20.

34. Felder CC, Briley EM, Axelrod J, Simpson JT, Mackie K, Devane WA. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA 1993;90:7656-7660.

35. Felder CC, Joyce K, Briley EM, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995;48:443-450.

36. Felder CC, Nielsen A, Briley EM, et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS 1996;393:231-235.

37. Fitton AG, Pertwee RG. Changes in body temperature and oxygen consumption rate of conscious mice produced by intrahypothalamic and intracerebroventricular injections of D9-tetrahydrocannabinol. Br J Pharmacol 1982;75:409-414.

38. Foltin RW, Fischman MW, Brady JV, et al. Motivational effects of smoked marijuana: Behavioral contingencies and low-probability activities. J Exp Anal Behav 1990;53:5-19.

39. Fride E, Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol 1993;231:313-314.

40. Fried PA, Makin JE. Neonatal behavioural correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol Teratol 1987;9:1-7.

41. Gardner EL. Cannabinoid interaction with brain reward systems—the neurobiological basis of cannabinoid abuse. In: Murphy L, Bartke A, eds. Marijuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press, 1992;275-335.

42. Gennings C, Carter, Jr. W.H., Martin BR. Response-surface analysis of morphine sulfate and D9-tetrahydrocannabinol interaction in mice. In: Lange N, Ryan L, eds. Case studies in biometry. New York: John Wiley & Sons, 1993; in press.

43. Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marihuana smoking on group interaction and individual behavior. Compr Psychiatry 1979;20:427-432.

44. Gérard CM, Mollereau C, Vassart G, Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 1991;279:129-134.

45. Hall W, Solowij N, Lemon J. The health and psychological consequences of cannabis use. Canberra: Australian Government Printing Service, 1994.

46. Hanus L, Gopher A, Almog S, Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 1993;36:3032-3034.

47. Heishman S, Huestis M, Henningfield J, Cone E. Acute and residual effects of marijuana: Profiles of plasma, THC levels, physiological subjective, and performance measures. Pharmacol Biochem Behav 1990;37:561-565.

48. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in the brain. Proc Natl Acad Sci USA 1990;87:1932-1936.

49. Heyser CJ, Hampson RE, Deadwyler SA. Effects of D9-tetrahydrocannabinol on delayed match to sample performance in rats: Alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 1993;264:294-307.

50. Hollister LE. Health aspects of cannabis. Pharmacol Rev 1986;38:1-20.

51. Howlett AC, Bidaut-Russell M, Devane WA, Melvin LS, Johnson MR, Herkenham M. The cannabinoid receptor: Biochemical, anatomical and behavioral characterization. TINS 1990;13:420-423.

52. Howlett AC, Evans DM, Houston DB. The cannabinoid receptor. In: Murphy L, Bartke A, eds. Marijuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press, 1992;35-72.

53. Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of D9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-D9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol 1992;16:283-290.

54. Hunter SA, Audette CA, Burstein S. Elevation of brain prostaglandin E2 levels in rodents by D1-THC. Prostaglandins Leukot Essent Fatty Acids 1991;43:185.

55. Hutchings DE, Brake SC, Morgan B. Animal studies of prenatal D9-tetrahydrocannabinol: Female embryolethality and effects on somatic and brain growth. Ann NY Acad Sci 1989;562:133-144.

56. Hutchings DE, Dow-Edwards D. Animal models of opiate, cocaine, and cannabis use. Clin Perinatol 1991;18:1-22.

57. Johnson MR, Melvin LS. The discovery of nonclassical cannabinoid analgetics. In: Mechoulam R, eds. Cannabinoids as therapeutic agents. Boca Raton: CRC Press, Inc., 1986;121-144.

58. Johnston LD, O'Malley PM, Bachman JG. National survey results on drug use from the monitoring the future study, 1975-1994. Washington, D.C.: U.S. Department of Health and Human Services, 1995.

59. Jones RT. Cannabis tolerance and dependence. In: Fehr KO, Kalant H, eds. Cannabis and health hazards. Toronto: Addiction Research Foundation, 1983;617-689.

60. Jones RT. Marijuana: health and treatment issues. Psychiatr Clin North Am 1984;7:703-712.

61. Jones RT, Benowitz N. The 30-day trip—Clinical studies of cannabis tolerance and dependence. In: Braude MC, Szara S, eds. Pharmacology of marihuana. New York: Raven Press, 1976;627-642.

62. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Ann NY Acad Sci 1976;282:221-239.

63. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol 1981;21:143S-152S.

64. Kandel DB, Davies M. Progression to regular marijuana involvement: phenomenology and risk factors for near daily use. In: Glantz M, Pickens R, eds. Vulnerability to drug abuse. Washington: American Psychological Association, 1992;211-253.

65. Karler R, Calder LD, Turkanis SA. Changes in CNS sensitivity to cannabinoids with repeated treatment: Tolerance and auxoesthesia. In: Sharp CW, eds. Mechanisms of tolerance and dependence. Washington, D.C.: U.S. Govt. Printing Office, 1984;312-322.

66. Kaymakcalan K, Ayhan IH, Tulunay FC. Naloxone-induced or postwithdrawal abstinence signs in D9-tetrahydrocannabinol-tolerant rats. Psychopharmacology 1977;55:243-249.

67. Kosten TR, Roundsville BJ, Babor TF, Spitzer RL, Williams JBW. Substance-use disorders in DSM-III-R. Brit J Psychiatry 1987;151:834-843.

68. Levitt M. Cannabinoids as antiemetics in cancer chemotherapy. In: Mechoulam R, ed. Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press, 1986;71-103.

69. Lichtman AH, Dimen KR, Martin BR. Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology 1995;119:282-290.

70. Lichtman AH, Martin BR. Cannabinoid induced antinociception is mediated by a spinal a2 noradrenergic mechanism. Brain Res 1991;559:309-314.

71. Lichtman AH, Martin BR. Spinal and supraspinal mechanisms of cannabinoid-induced antinociception. J Pharmacol Exp Ther 1991;258:517-523.

72. Lichtman AH, Martin BR. D9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology 1996;126:125-131.

73. Lichtman AH, Martin BR. The selective cannabinoid antagonist, SR 141716A, blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav 1997;57:7-12.

74. Little PJ, Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 1988;247:1046-1051.

75. Little PJ, Compton DR, Mechoulam R, Martin BR. Stereochemical effects of 11-OH-dimethylheptyl-D8-tetrahydrocannabinol. Pharmacol Biochem Behav 1989;32:661-666.

76. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 1992;89:3825-3829.

77. Mansbach RS, Nicholson KL, Martin BR, Balster RL. Failure of D9-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behav Pharmacol 1994;5:219-225.

78. Martin BR. Cellular effects of cannabinoids. Pharmacol Rev 1986;38:45-74.

79. Martin BR, Cabral G, Childers SR, Deadwyler S, Mechoulam R, Reggio P. International Cannabis Research Society meeting summary, Keystone, CO (June 19-20, 1992). Drug Alcohol Depend 1993;31:219-227.

80. Martin BR, Compton DR, Thomas BF, et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991;40:471-478.

81. Martin BR, Dewey WL, Harris LS, Beckner J. Marihuana-like activity of new synthetic tetrahydrocannabinols. Pharmacol Biochem Behav 1975;3:849-853.

82. Martin BR, Thomas BF, Razdan RK. Structural requirements for cannabinoid receptor probes. In: Pertwee RG, ed. Cannabinoid receptors. Academic Press Limited, 1995;36-85.

83. Mathew RJ, Wilson WH. The effects of marijuana on cerebral blood flow and metabolism. In: Murphy L, Bartke A, eds. Marijuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press, 1992;337-386.

84. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.

85. McGlothlin WH, West LJ. The marijuana problem: an overview. Am J Psychiatry 1968;125:370-378.

86. McMillan DE, Harris LS, Frankenheim JM, Kennedy JS. l-D9-trans-tetrahydrocannabinol in pigeons: Tolerance to the behavioral effects. Science 1970;169:501-503.

87. Mechoulam R, Feigenbaum JJ, Lander N, et al. Enantiomeric cannabinoids: stereospecificity of psychotropic activity. Experientia 1988;44:762-764.

88. Mechoulam R, Hanus L, Martin BR. The search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 1994;48:1537-1544.

89. Melvin LS, Johnson MR. Structure-activity relationships of tricyclic and nonclassical bicyclic cannabinoids. In: Rapaka RS, Makriyannis A, eds. Structure-activity relationships of the cannabinoids. Washington, D.C.: U.S. Government Printing Office, 1987;31-47.

90. Mendelson JH, Mello NK, Ellingboe J, Skupny AS, Lex BW, Griffin M. Marihuana smoking suppresses luteinizing hormone in women. J Pharmacol Exp Ther 1986;237:862-866.

91. Miles C, Congreve G, Givvins R, Marshman J, Devenga P, Hicks R. An experimental study of the effects of daily cannabis smoking on behavior patterns. Acta Pharm Toxicol 1974;34:1-44.

92. Miller NS, Gold MS. The diagnosis of marijuana (cannabis) dependence. J Subst Abuse Treat 1989;6:183-192.

93. Morgan B, Brake SC, Hutchings DE, Miller N, Gamagaris Z. D9-tetrahydrocannabinol during pregnancy in the rat: Effects on development of RNA, DNA, and protein in offspring brain. Pharmacol Biochem Behav 1988;31:365-369.

94. Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 1992;257:1248-1251.

95. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61-64.

96. Munson AE, Fehr KO. Immunological effects of cannabis. In: Fehr KO, Kalant H, eds. Cannabis and health hazards: Proceedings of an ARF/WHO scientific meeting on adverse health and behavioral consequences of cannabis use. Toronto: Addiction Research Foundation, 1983;257-354.

97. Nadler V, Mechoulam R, Sokolovsky M. The non-psychotropic cannabinoid (+)-(3S,4S)-7-hydroxy-delta-6-tetrahydrocannabinol-1,1-dimethylheptyl (HU-211) attenuates N-methyl-D-aspartate receptor-mediated neurotoxicity in primary cultures of rat forebrain. Neurosci Lett 1993;162:43-45.

98. Nahas G. Historical outlook of the psychopathology of cannabis. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, epidemiology, detection. Boca Raton, FL: CRC Press, 1993;95-99.

99. Negrete JC. Effects of cannabis on schizophrenia. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, epidemiology, detection. Boca Raton, FL: CRC Press, 1993; 105-112.

100. Newcombe MD. Understanding the multidimensional nature of drug use and abuse: the role of consumption, risk factors and protective factors. In: Glantz M, Pickens R, eds. Vulnerability to drug abuse. Washington: American Psychological Association, 1992;255-297.

101. O'Connell CM, Fried PA. An investigation of prenatal cannabis exposure and minor physical anomalies in a low risk population. Neurobehav Toxicol Teratol 1984;6:345-350.

102. Onaivi ES, Green MR, Martin BR. Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther 1990;253:1002-1009.

103. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: A quantitative autoradiographic study. Brain Res 1993;616:293-302.

104. Perez-Reyes M, Burstein SH, White WR, McDonald SA, Hicks RE. Antagonism of marihuana effects by indomethacin in humans. Life Sci 1991;48:507-515.

105. Perez-Reyes M, Hicks RE, Bumberry J, Jeffcoat AR, Cook CE. Interaction between marihuana and ethanol: Effects on psychomotor performance. Alcohol Clin Exp Res 1988;12:268-276.

106. Pertwee R. In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. In: Murphy L, Bartke A, eds. Marihuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press, 1992;165-218.

107. Pertwee RG, Greentree SG, Swift PA. Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with D9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 1988;27:1265-1270.

108. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991;40:695-700.

109. Pope H, Yurgelun-Todd D. The residual cognitive effects of heavy marijuana use in college students. JAMA 1996;275:521-527.

110. Razdan RK. Structure-activity relationships in cannabinoids. Pharmacol Rev 1986;38:75-149.

111. Rinaldi-Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240-244.

112. Robins LN, Regier DA. Psychiatric disorders in America. New York: Free Press, MacMillan, 1991.

113. Rodriguez de Fonseca F, Gorriti M, Fernandez RJJ, Palomo T, Ramos JA. Downregulation of rat brain cannabinoid binding sites after chronic D9-tetrahydrocannabinol treatment. Pharmacol Biochem Behav 1994;47:33-40.

114. Roffman RA, Stephens RS, Simpson EE, Whitaker DL. Treatment of marijuana dependence: preliminary results. J Psychoactive Drugs 1988;20:129-137.

115. Rounsaville BJ, Bryant K, Babor T, Kranzler H, Kadden R. Cross-system agreement for substance use disorders. Addiction 1993;88:89-98.

116. Schwartz RH. Chronic marihuana smoking and short-term memory impairment. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, epidemiology, detection. Boca Raton, FL: CRC Press, 1993; 61-71.

117. Selley DE, Stark S, Sim LJ, Childers SR. Cannabinoid receptor stimulation of guanosine-5'-0-(3-[35S]thio) triphosphate binding In rat brain membranes. Life Sci 1996;59:659-668.

118. Showalter V, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996;278:989-999.

119. Sim LJ, Hampson RE, Deadwyler SA, Childers SR. Effects of chronic treatment with D9-tetrahydrocannabinol on cannabinoid-stimulated [35]GTPgS autoradiography in rat brain. J Neurosci 1996;16:8057-8066.

120. Sim LJ, Selley DE, Xiao R, Childers SR. Differences in G-protein activation by m- and d-opioid, and cannabinoid receptors in rat striatum. Eur J Pharmacol 1996;307:97-105.

121. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994;270:219-227.

122. Smith PB, Welch SP, Martin BR. nor-Binaltorphimine specifically inhibits D9-tetrahydrocannabinol-induced antinociception in mice without altering other pharmacological effects. J Pharmacol Exp Ther 1993;268:1381-1387.

123. Solowij N, Michie P, Fox A. Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry 1995;37:731-739.

124. Stodieck SR. Phencyclidine (PCP): A psychotomimetic drug. Case report and review of literature. Schweiz Med Wochenschr 1983;113:1396-1402.

125. Struve FA, Straumanis JJ, Patrick G. Persistent topographic quantitative EEG sequelae of chronic marijuana use: a replication study and initial discriminant function analysis. Clin Electroencephalogr 1994;25:63-75.

126. Struve FA, Straumanis JJ, Patrick G, Price L. Topographic mapping of quantitative EEG variables in chronic heavy marihuana users: Empirical findings with psychiatric patients. Clin Electroencephalogr 1989;20:6-23.

127. Taschner KL. Psychopathology and differential diagnosis of so-called Cannabis psychoses. Fortschr Neurol Psychiatr 1983;51:235-248.

128. Terranova J-P, Storme J-J, Lafon N, et al. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology 1996;126:165-172.

129. Thomas BF, Compton DR, Martin BR, Semus SF. Modeling the cannabinoid receptor: A three-dimensional quantitative structure-activity analysis. Mol Pharmacol 1991;40:656-665.

130. Tsou K, Patrick S, Walker JM. Physical withdrawal in rats tolerant to D9-tetrahydrocannabinol precipated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995;280:R13-R15.

131. Tuchmann-Duplessis H. Effects of cannabis on reproduction. In: Nahas GG, Latour C, eds. Cannabis: Physiopathology, epidemiology, detection. Boca Raton, FL: CRC Press, 1993;187-192.

132. Vaysse PJ, Gardner EL, Zukin RS. Modulation of rat brain opioid receptors by cannabinoids. J Pharmacol Exp Ther 1987;241:534-539.

133. Vescovi PP, Pedrazzoni M, Michelini M, Maninetti L, Bernardelli F, Passeri M. Chronic effects of marihuana smoking on luteinizing hormone, follicle-stimulating hormone and prolactin levels in human males. Drug Alcohol Depend 1992;30:59-62.

134. Welch SP. Blockade of cannabinoid-induced antinociception by nor-binaltorphimine, but not N,N-diallyl-tyrosine-aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J Pharmacol Exp Ther 1993;256:633-640.

135. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992;262:10-18.

136. Wenger T, Croix D, Tramu G, Leonardelli J. Effects of D9-tetrahydrocannabinol on pregnancy, puberty, and the neuroendocrine system. In: Murphy L, Bartke A, eds. Marijuana/cannabinoids: Neurobiology and neurophysiology. Boca Raton, FL: CRC Press, 1992;539-560.

137. Wiley J, Lowe J, Balster R, Martin B. Antagonism of the discriminative stimulus effects of D9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 1995;275:1-6.